Last update Aug. 23, 2021
Barbiturate with hypnotic and sedative properties similar to amobarbital.
It has been used in insomnia and as a preanesthetic medication. Its use has been replaced by other drugs with less risk of abuse/dependence, overdose and withdrawal syndrome (Suddock 2020).
Oral or parenteral administration.
At the date of the last update, there was no available published data on its excretion in breast milk.
Its pharmacokinetic data (low molecular weight, low protein binding, prolonged half-life) make it probable that it will pass into breast milk in an amount that could be significant. On the other hand, its large volume of distribution (Breimer 1977) makes its excretion in breast milk difficult.
Product marketed in few countries.
Until more published data on this drug is available in relation to breastfeeding, known safer alternatives may be preferable, especially during the neonatal period and in the event of prematurity.
Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.
Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.
Thank you for helping to protect and promote breastfeeding.
e-lactancia is a resource recommended by Academy of Breastfeeding Medicine - 2012 of United States of America
Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM